BellBrook Labs Launches Ultra-Sensitive Methyltransferase Assay to Accelerate Epigenetic Drug Discovery
Thursday, 10 August 2017
Methyltransferases have become a major focus of drug discovery for cancer and other diseases driven by epigenetic factors. BellBrook Labs’ new, ultra-sensitive AptaFluor™ SAH Methyltransferase Assay eliminates cost and sensitivity barriers that are slowing the discovery of methyltransferase inhibitors. New AptaFluor SAH Methyltransferase Assay Schematic BellBrook Labs announces the launch of their latest drug discovery
- Published in Epigenetics, News, Uncategorized
No Comments
Previously Recorded Webinar – The New AptaFluor™ SAH Methyltransferase Assay: A Homogenous, Universal Assay Based on a Microbial Riboswitch
Monday, 31 July 2017
Epigenetic regulation has been shown to be a contributing factor in a variety of diseases, and discovery of methyltransferase inhibitors is an area of intense activity. Methyltransferase enzymes methylate a variety of substrates using S-adenosylmethionine (SAM) as the methyl donor leaving S-adenosylhomocysteine (SAH) as a common product. Since the difference between SAH and SAM is
- Published in Epigenetics, HTS Assays, Products
EZH2 Methyltransferase Inhibitors Hold Promise for Combating Neuropathic Pain
Friday, 21 July 2017
When people experience neuropathic pain, they often describe “pins and needles” sensations or burning, shooting, or stabbing pain that can be agonizing and difficult to bear. In some cases, neuropathic pain is so intense that the pressure of clothing or the weight of a bed sheet can cause misery. Chronic neuropathic pain can be caused
- Published in Emerging Targets, Epigenetics, HTS Assays
Sialyltransferases: Sugar Makes the Medicine Go Down?
Monday, 26 June 2017
Glycan structures decorate a wide variety of cell types—dotting the surface of blood cells, linked to lipid moieties on neurons, and studding the membrane of tumor cells. These carbohydrate structures create a cellular language that is translated by binding partners, eliciting specific downstream effects. And for some cancers, the effects can be devastating. Consider
- Published in Emerging Targets
BellBrook Labs Awarded NIH Grant to Develop a High Throughput cGAS Assay for Cancer and Autoimmune Disease Drug Discovery
Wednesday, 14 June 2017
BellBrook Labs was recently awarded a $288,000 SBIR Phase I grant from the National Institutes of General Medical Sciences (NIGMS) to develop an HTS assay for cyclic GAMP synthase, an enzyme that triggers immune responses to viruses and tumors. The new assay will be used in an effort to screen for cGAS enzyme modulators as
- Published in Emerging Targets, HTS Assays, News
On Demand Webinar: Development of Ectonucleotidase Assay Methods Using the Transcreener® HTS Assay Platform
Wednesday, 10 May 2017
View the Webinar On Demand at Anytime Ectonucleotidases are plasma membrane-bound enzymes with externally oriented active sites that metabolize nucleotides to nucleosides. One example is ectonucleoside triphosphate diphosphohydrolase-1, also known as CD39, ENTPD1, or NTPDase1. CD39 hydrolyzes ATP and ADP to AMP. Other ectonucleotidases such as CD73 process the AMP further into adenosine, which is
- Published in Uncategorized
Ectonucleotidases: An Outside Chance for Drug Development
Friday, 28 April 2017
Sometimes, the most intriguing cellular processes happen outside of the cell. Case in point: purinergic signaling pathways, in which extracellular receptors sense levels of purines in the extracellular milieu. The result? A wide array of effects on neuronal signaling, vascular tone, thrombosis, and immune function. But what controls the level of extracellular purines? Enter ectonucleotidases:
- Published in Emerging Targets, HTS Assays, Uncategorized
New Publication: HTS Method for Measuring Drug Residence Time
Tuesday, 25 April 2017
View our latest publication, “A High-Throughput Method for Measuring Drug Residence Time Using the Transcreener® ADP2 Assay” in SLAS Discovery. Inhibitor residence times are increasingly being used to prioritize molecules early in lead discovery programs. Current methods for determining residence time are low-throughput or require the synthesis of labeled ligands. Our goal was to create
- Published in Company, HTS Assays, News
Detecting Rho-GEF Activity Using the Transcreener® GDP Assay
Friday, 24 March 2017
Rho GTPases act as molecular switches to regulate the cytoskeletal dynamics underlying cell motility. Rho GEFs (guanine nucleotide exchange factors) positively regulate Rho GTPases by accelerating GDP dissociation and allowing formation of the active GTPase-GTP complex. Active Rho GTPases typically stimulate cell growth and migration, sometimes triggering tumorigenesis or invasion. Selectively disrupting GEF action using
- Published in Company, HTS Assays, Products
What to Look for in an ATPase Assay
Wednesday, 08 March 2017
If your organization utilizes ATPase assays, you must be sure to consider all available options on the market. After all, you must able to have reliable and accurate results, and without the right ATPase assay kit, that’s the best fit for your research this will be difficult. Of course, if you are just now starting
- Published in News
Recent Posts
-
Could an Inhibitor of Phosphodiesterase Activity be a Treatment for Alzheimer’s?
As we continue to increase our lifespan, diseas... -
Immuno-Oncology Drug Discovery: A CD39 Activity Assay for a Promising Target
What comes to mind when you think of immunother... -
How a Methyltransferase Activity Assay Could Help Identify Novel Breast Cancer Treatments
As estrogen receptor (ER) positive breast cance... -
Researchers Use ATPase Enzyme Assay to Study SMCHD1 Mutations
An ATPase enzyme assay – for more than ju... -
Researchers Employ GTPase Activity Assay to Investigate Rab Proteins
GTPases are in the limelight in biology and dru...
